NEW YORK, Sept. 6 – MediChem and Rigel Pharmaceuticals announced a two-year structural proteomics collaboration to search for new treatments in the area of ubiquitin ligases, which are involved in cell division and the progression of some cancers.

Under the terms of the deal, MediChem's Emerald BioStructures structural proteomics unit will express, purify, and crystallize proteins that Rigel is focusing on in its oncology program. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.